These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28659208)

  • 41. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?
    Giné CV; Espinosa IF; Vilamala MV
    Drug Test Anal; 2014; 6(7-8):819-24. PubMed ID: 24470121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland.
    Liakoni E; Dolder PC; Rentsch K; Liechti ME
    Swiss Med Wkly; 2015; 145():w14166. PubMed ID: 26218967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice.
    Schneier FR; Siris SG
    J Nerv Ment Dis; 1987 Nov; 175(11):641-52. PubMed ID: 3316490
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques.
    Caspar AT; Westphal F; Meyer MR; Maurer HH
    Anal Bioanal Chem; 2018 Jan; 410(3):897-912. PubMed ID: 28762065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mortality related to novel psychoactive substances in Scotland, 2012: an exploratory study.
    McAuley A; Hecht G; Barnsdale L; Thomson CS; Graham L; Priyadarshi S; Robertson JR
    Int J Drug Policy; 2015 May; 26(5):461-7. PubMed ID: 25477285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Self-Experiments with Psychoactive Substances: A Historical Perspective.
    Passie T; Brandt SD
    Handb Exp Pharmacol; 2018; 252():69-110. PubMed ID: 30478735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New Drugs of Abuse and Withdrawal Syndromes.
    Andrabi S; Greene S; Moukaddam N; Li B
    Emerg Med Clin North Am; 2015 Nov; 33(4):779-95. PubMed ID: 26493523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics.
    Meyer MR
    Arch Toxicol; 2016 Oct; 90(10):2421-44. PubMed ID: 27665567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation.
    Syrová K; Šíchová K; Danda H; Lhotková E; Jorratt P; Pinterová-Leca N; Vejmola Č; Olejníková-Ladislavová L; Hájková K; Kuchař M; Horáček J; Páleníček T
    Front Pharmacol; 2023; 14():1120419. PubMed ID: 36969854
    [No Abstract]   [Full Text] [Related]  

  • 50. Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States.
    Palamar JJ; Barratt MJ; Ferris JA; Winstock AR
    Am J Addict; 2016 Aug; 25(5):400-7. PubMed ID: 27419383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT.
    Jovel A; Felthous A; Bhattacharyya A
    J Forensic Sci; 2014 May; 59(3):844-6. PubMed ID: 24329118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis.
    Palma-Conesa ÁJ; Ventura M; Galindo L; Fonseca F; Grifell M; Quintana P; Fornís I; Gil C; Farré M; Torrens M
    J Psychoactive Drugs; 2017; 49(4):297-305. PubMed ID: 28569652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel psychoactive substances.
    Krabseth HM; Tuv SS; Strand MC; Karinen RA; Wiik E; Vevelstad MS; Westin AA; Øiestad EL; Vindenes V
    Tidsskr Nor Laegeforen; 2016 May; 136(8):714-7. PubMed ID: 27143461
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of use and acute toxicity associated with the use of NBOMe drugs.
    Wood DM; Sedefov R; Cunningham A; Dargan PI
    Clin Toxicol (Phila); 2015 Feb; 53(2):85-92. PubMed ID: 25658166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.
    Lawn W; Barratt M; Williams M; Horne A; Winstock A
    J Psychopharmacol; 2014 Aug; 28(8):780-8. PubMed ID: 24569095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intended and unintended use of cathinone mixtures.
    Guirguis A; Corkery JM; Stair JL; Kirton SB; Zloh M; Schifano F
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28657191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 58. Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe.
    Miliano C; Marti M; Pintori N; Castelli MP; Tirri M; Arfè R; De Luca MA
    Front Pharmacol; 2019; 10():1406. PubMed ID: 31915427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry.
    Caspar AT; Kollas AB; Maurer HH; Meyer MR
    Talanta; 2018 Jan; 176():635-645. PubMed ID: 28917801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in combinations and concentrations of drugs of abuse in fatal intoxication and driving under the influence cases.
    Edvardsen HE; Tverborgvik T; Frost J; Rogde S; Morild I; Waal H; Clausen T; Slørdal L; Vindenes V
    Forensic Sci Int; 2017 Dec; 281():127-133. PubMed ID: 29128652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.